Stomach bypass stent for liver scarring in obese patients
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a stomach bypass stent to treat liver scarring caused by fatty liver disease in people with obesity. If you have obesity and a confirmed liver condition called NASH with moderate scarring, this stent might help you achieve weight loss and improve your liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your body mass index (BMI) is 30 or higher.
- You have been diagnosed with or are suspected to have NASH-related liver scarring (fibrosis), confirmed by a liver biopsy.
- You have tried lifestyle changes and non-invasive treatments for at least 3 months without losing enough weight (non-diabetics: less than 5% weight loss; diabetics: less than 3% weight loss).
- You are not pregnant, do not have cirrhosis, and do not have other major health issues like uncontrolled diabetes, severe heart problems, or recent alcohol or drug abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This small study tests whether placing a gastric bypass stent can improve nonalcoholic fatty liver disease (fatty liver not caused by heavy alcohol). You may be considered if your liver fat is high on a special MRI scan and you meet several safety and medical history rules.
This study tests whether bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) improves severe nonalcoholic steatohepatitis (NASH) with advanced liver scarring in people who are obese. You may also need liver biopsies to confirm your liver disease before and after treatment.
This study looks at how the immune system relates to liver scarring in people with obesity who are getting gastric bypass surgery. If you qualify, you may help doctors better understand liver disease and who is at higher risk.
This trial looks at whether weight-loss (bariatric) surgery helps people with fatty liver disease, including “NASH,” and related liver scarring. If you have obesity and a confirmed liver fat diagnosis (and for NASH, biopsy-proven NASH with some fibrosis), the study may follow your outcomes after surgery.
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
This trial studies whether vertical sleeve gastrectomy (a type of weight-loss surgery) plus lifestyle coaching works better than another planned approach to improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It may help people reduce liver fat and inflammation, but you must be willing to follow study visits and possible random assignment.
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.